- Home
- ELVN vs JFR Comparison
ELVN vs JFR Comparison
Compare ELVN & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- JFR
- Stock Information
- Founded
- ELVN 2016
- JFR 2004
- Country
- ELVN United States
- JFR United States
- Employees
- ELVN N/A
- JFR N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- ELVN Health Care
- JFR Finance
- Exchange
- ELVN Nasdaq
- JFR Nasdaq
- Market Cap
- ELVN 1.2B
- JFR 1.1B
- IPO Year
- ELVN 2020
- JFR N/A
- Fundamental
- Price
- ELVN $20.73
- JFR $8.51
- Analyst Decision
- ELVN Strong Buy
- JFR
- Analyst Count
- ELVN 5
- JFR 0
- Target Price
- ELVN $41.20
- JFR N/A
- AVG Volume (30 Days)
- ELVN 747.2K
- JFR 621.7K
- Earning Date
- ELVN 08-12-2025
- JFR 01-01-0001
- Dividend Yield
- ELVN N/A
- JFR 11.31%
- EPS Growth
- ELVN N/A
- JFR N/A
- EPS
- ELVN N/A
- JFR N/A
- Revenue
- ELVN N/A
- JFR N/A
- Revenue This Year
- ELVN N/A
- JFR N/A
- Revenue Next Year
- ELVN N/A
- JFR N/A
- P/E Ratio
- ELVN N/A
- JFR N/A
- Revenue Growth
- ELVN N/A
- JFR N/A
- 52 Week Low
- ELVN $13.30
- JFR $7.61
- 52 Week High
- ELVN $30.03
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- ELVN 52.08
- JFR 72.96
- Support Level
- ELVN $19.22
- JFR $8.35
- Resistance Level
- ELVN $21.90
- JFR $8.29
- Average True Range (ATR)
- ELVN 1.49
- JFR 0.05
- MACD
- ELVN -0.19
- JFR 0.02
- Stochastic Oscillator
- ELVN 39.43
- JFR 100.00
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.